Skye Bioscience Inc [NASDAQ: SKYE] closed the trading session at $3.5 on 2025-08-29. The day’s price range saw the stock hit a low of $3.3899, while the highest price level was $3.605.
The stocks have a year to date performance of -43.55 percent and weekly performance of 6.38 percent. The stock has been moved at 22.81 percent over the last six months. The stock has performed -1.96 percent around the most recent 30 days and changed 76.77 percent over the most recent 3-months.
If compared to the average trading volume of 888.29K shares, SKYE reached to a volume of 159167 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Skye Bioscience Inc [SKYE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SKYE shares is $15.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SKYE stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Skye Bioscience Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 15, 2025. While these analysts kept the previous recommendation, William Blair raised their target price to Outperform. The new note on the price target was released on February 28, 2025, representing the official price target for Skye Bioscience Inc stock. Previously, the target price had yet another raise to $20, while Scotiabank analysts kept a Sector Outperform rating on SKYE stock.
The Price to Book ratio for the last quarter was 2.48, with the Price to Cash per share for the same quarter was set at 1.57.
SKYE stock trade performance evaluation
Skye Bioscience Inc [SKYE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.38. With this latest performance, SKYE shares dropped by -1.96% in over the last four-week period, additionally plugging by 22.81% over the last 6 months – not to mention a rise of 23.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SKYE stock in for the last two-week period is set at 49.81, with the RSI for the last a single of trading hit 0.26, and the three-weeks RSI is set at 0.31 for Skye Bioscience Inc [SKYE]. The present Moving Average for the last 50 days of trading for this stock 3.70, while it was recorded at 3.51 for the last single week of trading, and 2.93 for the last 200 days.
Skye Bioscience Inc (SKYE) Capital Structure & Debt Analysis
According to recent financial data for Skye Bioscience Inc. ( SKYE), the Return on Equity (ROE) stands at -72.75%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -60.78%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Skye Bioscience Inc’s Return on Invested Capital (ROIC) is -96.63%, showcasing its effectiveness in deploying capital for earnings.
Skye Bioscience Inc (SKYE) Efficiency & Liquidity Metrics
Based on Skye Bioscience Inc’s (SKYE) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
Skye Bioscience Inc (SKYE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Skye Bioscience Inc. (SKYE) effectively leverages its workforce, generating an average of -$2648125.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 6.09% and a Quick Ratio of 6.09%, indicating strong ability to cover short-term liabilities.
Skye Bioscience Inc [SKYE]: Institutional Ownership
There are presently around $66.12%, or 67.08%% of SKYE stock, in the hands of institutional investors. The top three institutional holders of SKYE stocks are: 5AM VENTURE MANAGEMENT, LLC with ownership of 10.18 million shares, which is approximately 26.3245%. VERSANT VENTURE MANAGEMENT, LLC, holding 2.01 million shares of the stock with an approximate value of $$16.08 million in SKYE stocks shares; and VERSANT VENTURE MANAGEMENT, LLC, currently with $$10.81 million in SKYE stock with ownership which is approximately 3.4914%.
